# Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Failure of First-Line Therapy With Platinum-based Doublet and Immunotherapy

> **NCT07594015** · PHASE2 · RECRUITING · sponsor: **University of Miami** · enrollment: 46 (estimated)

## Conditions studied

- Recurrent Endometrial Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT07594015
- **Lead sponsor:** University of Miami
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2031-06-01
- **Final completion:** 2031-06-01
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07594015

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07594015, "Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Failure of First-Line Therapy With Platinum-based Doublet and Immunotherapy". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT07594015. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*